Laboratory Examination in Hepatocelullar Carcinoma

Debie Anggraini


Hepatocellular carcinoma (HCC) is a malignant tumor originating from hepatocyte cells including primary malignant tumors of the epithelial liver. Hepatocellular carcinoma is the fifth most malignant in the world and the third largest cause of death of all malignancies. Diagnosis of HCC is obtained from the patient's history, examination of the patient, by imaging (ultrasonography, MRI or CT scan) and an increase in serum tumor biomarkers of alpha feto protein (AFP) (> 400 ng mL). Early diagnosis is important to increase the patient's life expectancy and only 30-40% of patients are diagnosed at an early stage. Biomarkers in HCC not only help in diagnosing but also predict prognosis or recurrence and in choosing therapy. The stability of miRNA in blood circulation makes miRNA an ideal candidate for use in the diagnosis and treatment of cancer. Objective: to briefly review all current information about HCC. Conclusion: HCC diagnosis is obtained from the patient's history, physical examination, imaging (ultrasonic, MRI or CT scan that shows the presence of a typical liver mass for HCC) and an increase in AFP serum (> 400 ng / mL). Biomarker examination and evaluation is still very limited, one of which is the examination of MicroRNAs


Biomarkers, hepatocelular carcinoma, microRNAs.

Full Text:



López P. Malignant Hepatic Neoplasms : Part 1 Hepatocellular carcinoma : the roles of liver biopsies and immunohistochemical studies and other important issues. 2015;462(1).


Hayes CN, Chayama K. MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma. 2016;

Tenggara DA, Parkin M. BAB I PENDAHULUAN A . Latar Belakang Masalah. 2010;408(2005):1–16.

Pollutri D, Gramantieri L, Bolondi L, Fornari F. TP53 / MicroRNA Interplay in Hepatocellular Carcinoma. 2016;1–20.

Liu S, Koh SSY, Lee CGL. Hepatitis B Virus X Protein and Hepatocarcinogenesis. (Figure 1):1–14.

Rawat S. Modulation of Apoptotic Signaling by the Hepatitis B Virus. 2014;(December 2012).

Zhang B, Han S, Feng B, Chu X, Chen L, Wang R. Hepatitis B virus X protein-mediated non-coding RNA aberrations in the development of human hepatocellular carcinoma. 2017;49(2):e293-12. Available from:

Hcc H. T h e r a n o s t i c s MicroRNAs Associated With HBV Infection And. 2014;4(12).

Lee YI, Hwang JM, Im JH, Lee YI, Kim NS, Kim DG, et al. Human Hepatitis B Virus-X Protein Alters Mitochondrial Function and Physiology in Human Liver Cells *. 2004;279(15):15460–71.

Sun J, Lu H, Wang X, Jin H. MicroRNAs in Hepatocellular Carcinoma : Regulation , Function , and Clinical Implications. 2013;2013.

Article R. MicroRNAs in Hepatocellular Carcinoma – Therapeutics and Beyond: A Systematic Review. 2017;

Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, et al. A Serum MicroRNA Panel as Potential Biomarkers for Hepatocellular Carcinoma Related with Hepatitis B Virus. 2014;9(9).

Sartorius K, Sartorius B, Chuturgoon AA. The biological and diagnostic role of miRNA ’ s in hepatocellular carcinoma. 2018;(March).

Wang L, Yue Y, Wang X, Jin H. Function and clinical potential of microRNAs in hepatocellular carcinoma ( Review ). 2015;3345–53.

Liu J, Zhang C, Zhao Y, Feng Z. MicroRNA control of p53. 2016;(January 2018).

Sidhu K, Kapoor NR, Pandey V, Kumar V. The “ macro ” world of microRNAs in hepatocellular carcinoma. 2015;5(March):1–8.

Luo J, Chen M, Huang H, Yuan T, Zhang M, Zhang K, et al. Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma. 2013;577–83.

Hung C, Hu T, Lu S, Kuo F, Chen C, Wang J, et al. Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus. 2016;720:714–20.

Bharali D, Jebur HB, Baishya D, Kumar S. Expression Analysis of Serum microRNA-34a and microRNA-183 in Hepatocellular Carcinoma. 2018;(September).

Xu L, Wei B, Hui H, Liu Y. Association of serum microRNA-125b and HBV-related hepatocellular carcinoma in Chinese Han patients. 2018;11(4):3699–703.

Schütte K, Schulz C, Link A, Malfertheiner P, Schütte K, Schulz C, et al. Current biomarkers for hepatocellular carcinoma : Surveillance , diagnosis and prediction of prognosis. 2015;7(2):139–49.

Lou J, Zhang L, Lv S. Biomarkers for Hepatocellular Carcinoma. 2017;




  • There are currently no refbacks.

Copyright (c) 2019 Health & Medical Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Creative Commons License   Health and Medical Journal This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.